|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 福沙那韦>> 市场分析报告 |
福沙那韦市场分析报告 |
|
Global Market Report of Fosamprenavir (CAS 226700-79-4) December 2024 Global Market Report of Fosamprenavir (CAS 226700-79-4) December 2024 Fructose-1,6-diphosphate (CAS 488-69-7) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Foscarnet (CAS 98048-97-6) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Global Market Report of Fosamprenavir calcium (CAS 226700-81-8) December 2024 CAS 226700-79-4 Fosamprenavir Chemical Report & Database ... Report & Database definitions: Name: Fosamprenavir: Fosamprenavir; ((3S)-Oxolan-3-yloxy)-N-((1S,2R)-3-{[(4-aminophenyl)sulfonyl](2-methylpropyl ... APPLICATIONS: Chemical or Reaction Intermediate The Fosamprenavir Report & Database gives Market Consumption ... CAS 226700-81-8 Fosamprenavir calcium Chemical Report & Database ... Consumption Report & Database definitions: Name: Fosamprenavir calcium: Fosamprenavir-calcium; Calcium [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl ... APPLICATIONS: Chemical or Reaction Intermediate The Fosamprenavir calcium Report & Database gives Market ... Anti-Infectives: Market Research Report This report analyzes the worldwide markets for Anti-Infectives in US$ Million. The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. ... HIV - KOL Insight and Consensus Outlook Modules ... ; ViiV Healthcare) forecast Lexiva/Telzir (fosamprenavir ;ViiV Healthcare) forecast Tivicay/(Trii ... The GSK Intelligence Dossier After two anemic years, GSK is ready to breathe new life. Despite intense competition from generics in the US, the company has finally reported a healthy growth in the third quarter of 2009. Now, eager to establish a forward-looking presence in emerging ... |